The bulk of AD research during the last 25 years has been Aβ-centric based on a strong faith
in the Amyloid Cascade Hypothesis which is not supported by the data on humans. To date …

Ten years of remarkable progress in understanding the fundamental biochemistry of
Alzheimer's disease have been followed by ten years of remarkable and increasing clinical …

Disease-modifying treatments for Alzheimer disease (AD) have focused mainly on reducing
levels of amyloid-β (Aβ) in the brain. Some compounds have achieved this goal, but none …

Amyloidopathies cause neurodegeneration in a substantial portion of the elderly population.
Improvements in long term health care have made elderly individuals a large and growing …

The number of people with Alzheimer's disease (AD) has never been greater and is set to
increase substantially in the decades ahead as the proportion of the population aged 65 …

The neurodegenerative disease first described almost 100 years ago by Alois Alzheimer is
predicted to be one of the major health problems of the 21st century. Alzheimer's disease …

Alzheimer's disease (AD) is the most common cause of cognitive impairment in older
patients and is expected to increase greatly in prevalence in the next future. It is …

Alzheimer's disease (AD) is the most common cause of dementia and accounts for one-half
to three-fourths of all cases of dementia. In the United States, AD is the leading cause of a …

Abstract Alzheimer's Disease (AD), the most prevalent neurodegenerative disease of aging,
affects one in eight older Americans. Nearly all drug treatments tested for AD today have …

Human clinical trials seek to ameliorate the disease states and symptomatic progression of
illnesses that, as of yet, are largely untreatable according to clinical standards. Ideally …